300404SZSE

Boji Pharmaceutical Co., Ltd.

博济医药

300404

Shenzhen Stock Exchange

Follow
48 announcements tracked· Last: May 18, 2026

Key Financials

Revenue¥220.2M
Net Profit¥16.5M
ROE1.54%
Debt Ratio34.06%
Monetary Funds¥163.5M
Receivables¥206.0M
Goodwill¥28.1M
Total Shares386.0M

Announcements

48 total

Legal Opinion from Beijing Kangda (Guangzhou) Law Firm on the 2025 Annual Shareholders' Meeting of the Company

Share PledgeShareholding Change DisclosureCapital Reduction

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on the Repurchase and Cancellation of Some Restricted Stocks to Notify Creditors

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Continuous Supervision Tracking Report for the Company's 2025 Annual Report by GF Securities Co., Ltd.

Shareholder Share IncreaseShareholding Change DisclosureCapital Reduction

Summary Report on the Company's 2023 Issuance of Stocks to Specific Objects by GF Securities Co., Ltd.

Shareholder Share IncreaseShare PledgeShareholding Change Disclosure

2025 Annual Remuneration of Directors and Senior Management and the Remuneration Plan for 2026

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on the Proposed Reappointment of the Accounting Firm

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

2025 Annual Independent Director Work Report (Li Huayi)

Convertible BondsShareholding Change DisclosureCapital Reduction

2025 Annual Independent Director Work Report (Chen Qing)

Convertible BondsShareholding Change DisclosureCapital Reduction

2025 Annual Independent Director Work Report (Xie Kang)

Convertible BondsShareholding Change DisclosureCapital Reduction

Announcement on Holding an Online Explanation Meeting for the Company's 2025 Annual Report

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Guangfa Securities Co., Ltd. Verification Opinion on Boji Medical Technology Co., Ltd.'s 2025 Annual Internal Control Evaluation Report

Share Repurchase CompletionShareholder Share IncreaseShare Pledge

Internal Control Audit Report

Share PledgeShareholding Change DisclosureCapital Reduction

2025 Annual Internal Control Evaluation Report

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Remuneration Management System for Directors and Senior Management (April 2026)

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Changes in Accounting Policies

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Provision for Asset Impairment Losses, Credit Impairment Losses, and Write-off of Assets

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on the Company's Receipt of Drug Clinical Trial Approval Notice

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Legal Opinion Letter from Beijing Kangda (Guangzhou) Law Firm on the Company's Repurchase and Cancellation of Certain Restricted Stocks

Share PledgeShareholding Change DisclosureCapital Reduction

Review Opinion of the Compensation and Assessment Committee of the 5th Board of Directors on the Repurchase and Cancellation of Certain Restricted Stocks

Share Repurchase PlanShareholding Change DisclosureCapital Reduction

Announcement on the Repurchase and Cancellation of Certain Restricted Stocks

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Guangfa Securities Co., Ltd. Verification Opinion on the Confirmation of 2025 Routine Related Transactions and Estimated Routine Related Transactions for 2026 by Boji Medical Technology Co., Ltd.

Share PledgeShareholding Change DisclosureCapital Reduction

Announcement on Confirming 2025 Routine Related Transactions and Estimated Routine Related Transactions for 2026

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Providing Financing Guarantees for Subsidiaries

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Providing Business Contract Guarantees for Subsidiaries

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Applying for Financing Credit Limits from Financial Institutions

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Notice of the 2025 Annual Shareholders' Meeting

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Resolution Announcement of the 20th Meeting of the 5th Board of Directors

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on the Company's Profit Distribution Plan for 2025

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Q1 2026 Report

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Special Report on Fund Raising Storage, Management, and Usage for 2025

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Annual Verification Report on Fund Raising Storage, Management, and Usage

Share Repurchase CompletionShare PledgeShareholding Change Disclosure

Guangfa Securities Co., Ltd. Verification Opinion on the Company's 2025 Annual Fund Raising Storage, Management, and Usage

Share PledgeShareholding Change DisclosureCapital Reduction

Report on the Evaluation of the Accounting Firm's Performance in 2025 and the Audit Committee's Supervision Responsibilities

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Special Audit Explanation on Non-Operating Fund Occupation and Other Related Fund Transactions

Share Repurchase CompletionShare PledgeShareholding Change Disclosure

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for 2025

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Special Report on the Board's Self-Examination of the Independence of Independent Directors

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

2025 Annual Audit Report

Share PledgeShareholding Change DisclosureCapital Reduction

2025 Annual Report

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Summary of the 2025 Annual Report

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Signing the 'Technology Transfer Contract'

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on the Company Obtaining an Invention Patent Certificate

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on changes related to the Daoyuan Angel Equity Investment Fund

Share Repurchase PlanShareholding Change DisclosureCapital Reduction

Announcement on the Full-owned Subsidiary Obtaining the Drug Clinical Trial Approval Notice

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Results of Repurchased Share Reduction and Share Changes

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on the First Repurchase of Shares

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Resolutions Announcement of the Nineteenth Meeting of the Fifth Board of Directors

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Announcement on Share Repurchase and Centralized Bidding Reduction Plan

Share Repurchase CompletionShareholding Change DisclosureCapital Reduction

Notes & Comments

Sign in to leave a comment or private note.

Loading…